Vericiguat novel heart failure drug

11 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Vericiguat (Verquvo) — Novel Heart Failure Therapy
What It Is
FDA and EMA approved in 2021
First-in-class soluble guanylate cyclase (sGC) stimulator
Indication
Chronic heart failure with reduced ejection fraction (HFrEF)
Especially after recent decompensation (hospitalization or IV diuretics)
Goal: Reduce cardiovascular death and HF-related hospitalizations
Mechanism of Action
Stimulates sGC → increases cGMP
Effects: Vasodilation, improved myocardial function, reduced cardiac stress
Restores impaired NO–cGMP signaling in heart failure
Why Novel
First-in-class with a unique mechanism
Works via cGMP pathway, unlike ACE inhibitors, ARBs, or SGLT2 inhibitors
Targets endothelial dysfunction directly
Side Effects
Most common: Hypotension, anemia
Contraindicated in pregnancy
Keywords: Vericiguat, Verquvo, sGC stimulator, heart failure, HFrEF, cGMP pathway, endothelial dysfunction, cardiovascular therapy
Hashtags: #HeartFailure #Vericiguat #sGCStimulator #HFrEF #CardioInnovation #NovelDrug #Verquvo
Categoria
Cardiology
Commenta per primo questo video.

Prossimo